Sodium Citrate and Citric Acid Oral Solution USP

Manufacturer
Pharmaceutical Associates, Inc.
Effective date
2024-11-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
full-release
Hydrated at
2026-05-31 21:17:18

Label at a glance#

ProductSodium Citrate and Citric Acid
Active ingredientSODIUM CITRATE, ANHYDROUS CITRIC ACID
Label structure17 sections

Indications and uses

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contra...

Dosage and administration

Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

Storage and handling

Keep tightly closed.  Store at controlled room temperature, 20°-25°C (68°-77°F).  Protect from freezing.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

A Sugar-Free Systemic Alkalizer

DESCRIPTION

DESCRIPTION SECTION

Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base. It is a nonparticulate neutralizing buffer.

Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)

CITRIC ACID Monohydrate 334 mg (0.32 Molar)

Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).

Sodium citrate contains the following inactive ingredients: flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients on sodium-restricted diets or with severe renal impairment.

PRECAUTIONS

PRECAUTIONS SECTION

Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.

To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch..

OVERDOSAGE

OVERDOSAGE SECTION

Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

For Systemic Alkalization

SPL UNCLASSIFIED SECTION

Usual Adult Dose

SPL UNCLASSIFIED SECTION

2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose

SPL UNCLASSIFIED SECTION

1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. For children under two years of age, use is based on consultation with a physician.

As a neutralizing buffer

SPL UNCLASSIFIED SECTION

3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Citrate and Citric Acid Oral Solution USP (colorless, grape flavor) is supplied in the following oral dosage forms:

NDC 0121-0595-16: 16 fl oz (473 mL) bottle

NDC 0121-0595-15: 15 mL unit dose cup. Case contains 100 unit-dose cups of 15 mL (NDC 0121-0595-00), packaged in 10 trays of 10 unit-dose cups each.

NDC 0121-1190-30: 30 mL unit dose cup. Case contains 100 unit-dose cups of 30 mL (NDC 0121-1190-00) packaged in 10 trays of 10 unit-dose cups each.

.

STORAGE:

STORAGE AND HANDLING SECTION

Keep tightly closed.  Store at controlled room temperature, 20°-25°C (68°-77°F).  Protect from freezing.

SPL UNCLASSIFIED SECTION

Rx ONLY

MANUFACTURED BY:

Pharmaceutical Associates, Inc.
Greenville, SC 29605
www.paipharma.com

R03/22

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0121-0595-16

NSN 6505-01-097-4766

Sodium Citrate and Citric Acid Oral Solution USP

500 mg/334 mg per 5 mL

A SUGAR-FREE SYSTEMIC ALKALIZER

Each teaspoonful (5 mL) contains:

Sodium Citrate Dihydrate..........500 mg

Citric Acid Monohydrate............334 mg

Each mL provides 1 mEq Sodium Ion and is

equivalent to 1 mEq Bicarbonate (HCO3).

Rx ONLY

16 fl oz (473 mL)

Pharmaceutical Associates, Inc.

Greenville, SC 29605

473 mL Bottle Label473 mL Bottle Label

PRINCIPAL DISPLAY PANEL - 15 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Delivers 15 mL

NDC 0121-0595-15

S ODIUMC ITRATEand
C ITRICA CIDO RAL
S OLUTIONUSP (Sugar Free)

1.5 g/ 1 g per 15 mL

SHAKE WELL-DILUTE AS DIRECTED

Package Not Child-Resistant

Rx ONLY

PHARMACEUTICAL ASSOCIATES, INC.

GREENVILLE, SC 29605

SEE INSERT

30 mL Unit Dose Cup Label30 mL Unit Dose Cup Label

PRINCIPAL DISPLAY PANEL - 30 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Delivers 30 mL

NDC 0121-1190-30

S ODIUMC ITRATEand
C ITRICA CIDO RAL
S OLUTIONUSP (Sugar Free)

3 g/ 2 g per 30 mL

SHAKE WELL-DILUTE AS DIRECTED

Package Not Child-Resistant

Rx ONLY

PHARMACEUTICAL ASSOCIATES, INC.

GREENVILLE, SC 29605

SEE INSERT

30 mL Unit Dose Cup Label30 mL Unit Dose Cup Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
543014citric acid 334 MG / sodium citrate 500 MG in 5 mL Oral SolutionPSN10
543014citric acid 66.8 MG/ML / sodium citrate 100 MG/ML Oral SolutionSCD10
543014citric acid 1002 MG / sodium citrate 1500 MG per 15 ML Oral SolutionSY10
543014citric acid 2004 MG / sodium citrate 3000 MG per 30 ML Oral SolutionSY10
543014citric acid 334 MG / sodium citrate 500 MG per 5 ML Oral SolutionSY10

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0121-0595-00Sodium Citrate and Citric Acid10 in 1 CASESOLUTION1010
0121-0595-00Sodium Citrate and Citric Acid10 in 1 TRAYSOLUTION1010
0121-0595-15Sodium Citrate and Citric Acid15 mL in 1 CUP, UNIT-DOSESOLUTION1510
0121-0595-16Sodium Citrate and Citric Acid473 mL in 1 BOTTLESOLUTION47310
0121-0595-30Sodium Citrate and Citric Acid10 in 1 CASESOLUTION1010
0121-0595-30Sodium Citrate and Citric Acid10 in 1 TRAYSOLUTION1010
0121-1190-00Sodium Citrate and Citric Acid10 in 1 CASESOLUTION1010
0121-1190-00Sodium Citrate and Citric Acid10 in 1 TRAYSOLUTION1010
0121-1190-30Sodium Citrate and Citric Acid30 mL in 1 CUP, UNIT-DOSESOLUTION3010

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0121-0595SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE AND CITRIC ACID MONOHYDRATE) SOLUTION [PHARMACEUTICAL ASSOCIATES, INC.]10Current NDC, Legacy NDC, 6 package rows20241115_63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd5.zip
0121-1190SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE AND CITRIC ACID MONOHYDRATE) SOLUTION [PHARMACEUTICAL ASSOCIATES, INC.]10Current NDC, Legacy NDC, 3 package rows20241115_63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd5.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0121-0595-00ML - Milliliter0121-059504f1b315-0b19-43dc-8880-02107f0a444112017-05-03
0121-0595-15ML - Milliliter0121-059539755d14-96ba-449a-974a-ee51f0dad5b512013-02-13
0121-0595-16ML - Milliliter0121-05958504dba4-d1e6-4997-bd8e-7e256ff3034912013-02-13
0121-0595-30ML - Milliliter0121-0595810c9f41-7bae-4f1c-9218-25d078607d7512013-02-13
0121-1190-00ML - Milliliter0121-1190f53a575f-57da-411a-8b6c-354d9bfe3c2d12017-05-03
0121-1190-30ML - Milliliter0121-11902a1f3afe-b13d-42e0-bf3d-ba0f7a6ceda412017-05-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CITRIC ACID MONOHYDRATEACTIVE INGREDIENT2968PHW8QP1
SODIUM CITRATEACTIVE INGREDIENT1Q73Q2JULR1
ANHYDROUS CITRIC ACIDACTIVE MOIETYXF417D3PSL1
POLYETHYLENE GLYCOLSINACTIVE INGREDIENT3WJQ0SDW1A1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
SODIUM BENZOATEINACTIVE INGREDIENTOJ245FE5EU1
SORBITOLINACTIVE INGREDIENT506T60A25R1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0121-05950121-0595-16, 0121-0595-15, 0121-0595-00, 0121-0595-30
0121-11900121-1190-30, 0121-1190-00

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 24 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / ORAL22602 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SORBITOLSORBITOL506T60A25RSOLUTION / ORAL29268 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSOLUTION / ORAL660 mgExact identifier — unii+route+dosage form
8 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium Citrate and Citric AcidSODIUM CITRATE AND CITRIC ACID MONOHYDRATEPharmaceutical Associates, Inc.63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd52024-11-13Adverse reactionsExact identifier
ndc (package): 0121-0595-30
ndc (package): 0121-0595-16
ndc (package): 0121-1190-30
ndc (package): 0121-0595-00
ndc (package): 0121-0595-15
ndc (package): 0121-1190-00
ndc (product): 0121-0595
ndc (product): 0121-1190
ndc11 (package): 00121119000
ndc11 (package): 00121059515
ndc11 (package): 00121059530
ndc11 (package): 00121059500
ndc11 (package): 00121059516
ndc11 (package): 00121119030
spl id: 26ce1be6-a69a-63f8-e063-6394a90ad637
spl set id: 63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd5

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.